Non Small Cell Lung Cancer - gefitinib - EGFR mutation + CREBBP mutation

Association details:

Biomarker:	EGFR mutation + CREBBP mutation
Cancer:	Non Small Cell Lung Cancer
Drug:	gefitinib (EGFR inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: B - Late Trials

Source:

Mol Oncol

Title:

NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study

Published date:

10/21/2023

Excerpt:

The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)....In patients with CREBBP co-mutations, the gefitinib group had a longer DFS than the cis/vin group...

DOI:

10.1002/1878-0261.13542